---
layout: post
title: "长春高新：公司重组人生长激素注射液增加特发性矮小（ISS）适应症已于去年纳入优先评审"
date: 2022-04-29 15:12:07 +0800
categories: cailianshe
tags: 财联社新闻
---
<p style="display:none;height:1px;overflow:hidden;"> </p><!-- EM_StockImg_Start --><p style="text-align:center;"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=0.000661&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 000661_0" data-code="K 000661|0|2" data-code2="K 000661|0|6|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></p><!-- EM_StockImg_End --><p>长春高新在接受机构调研时表示，公司重组人生长激素注射液增加特发性矮小(ISS)适应症已于去年纳入优先评审，预计进展顺利的情况下今年能够获得批准。<br /></p><p class="em_media">（文章来源：财联社）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202204292366285639>

[返回财联社新闻](//finews.withounder.com/category/cailianshe.html)｜[返回首页](//finews.withounder.com/)